Verve Therapeutics announced that VERVE-101 has been awarded the Innovation Passport for the treatment of heterozygous familial hypercholesterolemia under the Innovative Licensing and Access Pathway by the Medicines and Healthcare products Regulatory Agency, the regulatory body of the United Kingdom. The ILAP aims to accelerate time to market and facilitate patient access to innovative medicines. VERVE-101 is a novel, investigational gene editing medicine designed to be a single-course treatment that permanently turns off the PCSK9 gene in the liver to durably lower disease-driving low-density lipoprotein cholesterol. Innovation Passport is the first step in the ILAP process and is awarded for a medicinal product addressing a condition that is life-threatening or seriously debilitating and where there is a significant patient or public health need.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VERV:
- Verve Therapeutics Announces VERVE-101 Awarded Innovation Passport by the UK MHRA for the Treatment of Heterozygous Familial Hypercholesterolemia
- 2 High-Risk, High-Reward Stock Bets Cathie Wood Is Taking Into 2023
- Verve Therapeutics initiated with a Neutral at Cantor Fitzgerald
- Sell these stocks now, proven algorithm says
- Short Report: Bears pounce on disappointing drug news from Gossamer and Verve